anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a disease that causes an abnormal accumulation of fat in the liver, triggering inflammation and fibrosis, the mechanism of which is not fully understood and for which there is a lack of specific drug therapy. Far-infrared radiation (FIR) has demonstrated evident therapeutic efficacy across various diseases, and novel nanomaterial graphene patches can emit it through electric heating. This study aimed to investigate the potential protective effects of FIR against MAFLD. Mice were fed with a MCD diet to mimic MAFLD progression, and histopathology analysis, biochemical analysis, RT-qPCR, and Western blotting analysis were performed to assess the effect of FIR on MAFLD in vivo. The effect of FIR treatment on MAFLD in vitro was investigated by biochemical analysis and gene expression profiling of hepatocytes. Mice subjected to the MCD diet and treated with FIR exhibited reduced hepatic lipid deposition, inflammation, fibrosis and liver damage. The therapeutic effect exerted by FIR in mice may be caused by the enhancement of AMPK phosphorylation and inhibition of the TGFβ1-SMAD2/3 pathway. Besides, FIR intervention alleviated MAFLD in hepatocytes in vitro and the results were verified by gene expression profiling. Our results revealed a promising potential of FIR as a novel therapeutic approach for MAFLD.
Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new derivatives of tropan-2-aldoxime of the formula (I), any their mixture or their pharmaceutically acceptable salt where R means hydrogen atom or alkyl; R 3  means CH= NOR 1  where R 1  means hydrogen atom or alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl or aryl possibly substituted with COOH, COO-alkyl or phenyl; R 4  means phenyl that can be substituted once or some times with substituents taken from the group including halogen atom, CF 3 , CN, NO 2  or alkyl, benzyl or naphthyl. These compounds show valuable therapeutic properties as reuptake inhibitors of monoamine neurotransmitters, i. e. dopamine, serotonin, epinephrine. Invention describes also a pharmaceutical composition for inhibition of reuptake of monoamine neurotransmitters based on compounds of the formula (I) and a method of treatment of an animal organism (including human) with disorders or diseases where compounds of the formula (I) show inhibiting effect of dopamine reuptake. EFFECT: improved method of synthesis, enhanced effectiveness of treatment. 12 cl, 14 ex
Described herein are syringe caps including a plug portion and a protruding member extending from one end of the plug portion. The protruding member can extend a length greater than a depth of an accumulated component in the syringe. Also described herein, are systems including a syringe containing a composition and a syringe cap. The syringe cap can include a luer-lock with a projecting member that projects into the syringe. The projecting member can assist in creating a tunnel through the accumulated material thereby allowing degassing of the composition. The projecting member can also help to prevent accumulation of a radiopaque visualization agent or contrast agent that may accumulate along one end of the syringe.
Bioresource study to identify pathways responsible for VOC production: A total of 192 patients will be recruited to provide samples to create a pancreatic biobank. This will be comprised of two groups, each containing 96 patients: (i) patients undergoing resection for pancreatic ductal adenocarcinoma (PDAC); (ii) control patients undergoing pancreatic resection for benign pancreatic disorders (e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis). The following biosamples will be collected from each patient: breath, saliva, blood, urine, pancreatic tissue, duodenal aspirate. Collected samples will be stored in a biobank and will be utilised in a wide range of studies to investigate the mechanisms of VOC production in PDAC. The following analyses will be undertaken: volatolomics, metabonomics / lipidomics, metagenomics / microbiome analysis, transcriptomics, and culture experiments (to establish bacterial, immune and organoid cultures).

VAPOR 1 clinical study: A total of 771 patients will be recruited for the development of this non-invasive PDAC detection model. This will be comprised of three groups, each containing 257 patients: (i) patients with PDAC; (ii) control patients with specified benign pancreatic disorders (new-onset diabetes mellitus, or chronic pancreatitis); (iii) control patients with non-specific gastrointestinal symptoms but a radiologically-normal pancreas. Participants will be required to fast for 6 hours prior to breath sampling. After rinsing their mouth with water, patients will be asked to provide breath samples by exhaling into single-use breath collection bags. Breath will be transferred using a precision pump into thermal desorption (TD) storage tubes. Breath samples will be analysed in accordance with existing quality-controlled processes.
Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
Imatinib is the first-line treatment for advanced GIST with a satisfactory response rate, but complete remission rarely happens. Besides, drug resistance can occur during the treatment and the median time of drug resistance is about 20-24 months. Once drug resistance occurs, the patient's condition will progress rapidly. As a salvage treatment, the effect of increasing the dose of imatinib or switching to sunitinib is very limited. Progress after imatinib treatment usually involves two conditions, focal progression and extensive progression. For local progression, all resistant lesions can be completely resected; extensive progression refers to resistance progression in multiple sites, and progressive lesions cannot be completely removed. The present study is aimed to assess the benefits of surgical resection of imatinib-resistant lesions in patients with localized disease.
Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
PROBLEM TO BE SOLVED: To obtain a liquid crystal hydrated composition excellent in stability and safety, also excellent in hydrating power to sustain skin dampishness, and having emulsification effect, by using a specific cholesterol ester-included product in combination with water. SOLUTION: This hydrated composition comprises water and a cholesterol clathrate prepared by including a cholesterol ester into a hydroxyalkylated cyclodextrin. The respective amounts of the hydroxyalkylated cyclodextrin, the cholesterol ester, and the water should fall within a range given by the slanting lines in the phase diagram shown in the figure. The hydrated composition is useful as an oil-in-water type emulsified cosmetic. It is recommended that 0.01-20wt. of this composition is contained in the objective oil-in-water type emulsified cosmetic which is produced by mixing and agitating the hydroxyalkylated cyclodextrin, cholesterol ester and water to form a liquid crystal and then is then further agitated and mixed with other ingredients to effect emulsification.
Obesity is a complex chronic disease and common comorbidity in kidney failure and is the leading causes of death and disability in this population. Guidelines do not specifically address the preferred weight management option(s) for obesity while on dialysis. Large body size is a limiting factor for consideration of a kidney transplantation. We report on a successful bariatric surgery with a young adult after 5.5 years on dialysis with hope for a future transplant. Success was demonstrated with progressive weight loss without adverse changes in renal clinical markers accompanied by improvements in exercise tolerance and health status thereby improving her suitability for a kidney transplant. Further studies and guidelines are needed to address weight loss options for those with obesity on dialysis and want to lose weight.
Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
The invention relates to the technical field of medicaments, and particularly relates to a composition for teriparatide injection, and a preparation method and preparation thereof. The composition for teriparatide injection comprises teriparatide, a freezing and drying protecting agent and a pH regulator, wherein the mass ratio of the teriparatide to the freezing and drying protecting agent is 1:(10-100000). The composition for teriparatide injection is simple in formula; the freezing and drying protecting agent ensures that the teriparatide is not degraded in preparation and preservation processes; and the pH regulator is used for regulating the pH value in a preparation process and regulating the pH value after the composition for teriparatide injection is redissolved, so as to maintain the stability of the teriparatide. The used auxiliary materials are safe, and do not cause toxic reaction. Therefore, the composition for teriparatide injection provided by the invention is good in stability, simple and reasonable in formula, and good in redissolving performance, and can be prepared into powder-injection or injection and is needless to be prepared into a pen-type injector. Thus, the production technology is simple.
The passage of human urine through a bed of adsorbent material results in the adsorption from the urine of antineoplastic substances as determined by in vitro tissue culture techniques utilizing human tumor cells. The adsorbent yields two antineoplastic fractions upon sequential elution. Elution of the low-molecular weight antineoplastic fraction is accomplished by elution with cold aqueous acetone at slightly alkaline pH. Thereafter, elution of the high molecular weight antineoplastic fraction is accomplished by elution with a cold aqueous acetone-glycerol mixture at slightly alkaline pH. The antineoplastic activities of these fractions are determined by tissue culture techniques employing a variety of human neoplastic cells. Furthermore, the high molecular weight fraction, the antineoplastic urinary protein, also inhibits the progression and causes regression of certain human tumor cells implanted in the nude mouse.
PURPOSE:To obtain deodorant agent of body smell and uraroma capable of oral administrating and essentially inhibiting generation of uncomfortable odor such as body smell, ozostomia or uraroma, containing phytic acid and salt thereof as active ingredient. CONSTITUTION:&?At least one material selected from phytic acid and salt thereof is used as active ingredient, dissolved in water and directly used as deodorant agent. Otherwise, excipient is added and pulverized, further granulated and made to preparation such as granular agent or tablet to afford the aimed deodorant agent. Dose of the preparation is 1-500mg calculated as phytic acid for one day, an adult. Dosing is facilitated with a shape of food and drink or table luxury. Uncomfortable odor such as ozostomia, sweat odor, fat odor, hygienic odor or glucosuria odor, etc., is able to be removed.
Adhesion may occur due to the excessive production of fibrous tissue during the process of wound healing. Abdominal adhesion could play a role on intestine obstruction which will lead to lack of blood flow to the blocked part of the intestine or peritonitis. Improving surgical skills, cleaning wound before closure or using physical barrier between the incision site and abdominal wall can lower the incidence of abdominal adhesion.

In this study, participant who meets the eligibility criteria will be enrolled and randomized to either the treatment or control group. During the surgery period, subject will have the DividPro film implantation or only the standard care procedure right before the closure of the surgical wound. Participants will be instructed to return for visits on day 7, month 1, 3, 6 and 12. Adverse event, clinical laboratory test, vital sign and physical examination will be tested and recorded during the course of the study as the items of safety assessment. In addition, symptom related to tissue adhesion, visceral sliding test and quality of life questionnaire will also be assessed as the parameters of efficacy at the predetermined time points throughout the study .
BACKGROUND: Elevated aortic valve gradients are common after transcatheter aortic valve implantation for degenerated surgical aortic valve replacement bioprostheses, but their clinical impact is uncertain.
METHODS: A total of 12 122 patients who underwent transcatheter aortic valve implantation-in-surgical aortic valve replacement from November 2011 to December 2019 in the Society of Thoracic Surgery/American College of Cardiology Transvalvular Therapeutics Registry were included. The primary outcome was a composite of 1-year all-cause mortality, stroke, myocardial infarction, or valve reintervention. Secondary outcomes included 1-year all-cause mortality, readmission, and change from baseline 12-question self-administered Kansas City Cardiomyopathy Questionnaire-Overall Summary Score. Due to nonlinearity observed with restricted cubic splines analysis, a Cox regression analysis with aortic valve mean gradient modeled as a spline-continuous variable (with 20 mm Hg as a cutoff) was used to study the 1-year composite outcome and mortality.
RESULTS: The composite outcome occurred most frequently in patients with aortic valve mean gradient ≥30 and <10 mm Hg, as compared with those with 10 to 20 and 20 to 30 mm Hg ranges (unadjusted rates, 13.9%, 12.1%, 7.5%, and 6.5%, respectively; P=0.002). When the mean aortic valve gradient was ≥20 mm Hg, higher gradients were associated with greater risk of the 1-year composite outcome (adjusted hazard ratio, 1.02 [1.02-1.03] per mm Hg; P<0.001) and 1-year mortality (adjusted hazard ratio, 1.02 [1.00-1.03] per mm Hg; P=0.007). Whereas when the mean aortic valve gradient was <20 mm Hg, higher gradients were not significantly associated with the composite outcome (adjusted hazard ratio, 0.99 [0.98-1.003] per mm Hg; P=0.12) but were associated with lower 1-year mortality (adjusted hazard ratio, 0.98 [0.97-0.99] per mm Hg; P=0.007).
CONCLUSIONS: The relationship between postprocedural aortic valve mean gradient after transcatheter aortic valve implantation-in-surgical aortic valve replacement and clinical outcomes is complex and nonlinear, with relatively greater adverse events occurring at low and high gradient extremes. Further study of factors mediating the relationship between postprocedural gradients and clinical outcomes, including low-flow states, is necessary.
Pyroptosis, a programmed cell death process, is vital for the immune response against microbial infections and internal danger signals. Recent studies have highlighted the importance of protein palmitoylation, a modification that involves attaching palmitate to cysteine residues, in regulating key proteins involved in pyroptosis. Palmitoylation of cGAS at residue C474 by ZDHHC18 affects its enzymatic activity and DNA binding ability. Similarly, ZDHHC9 promotes cGAS activity through palmitoylation at residues C404/405. NLRP3 palmitoylation at residue C844, mediated by ZDHHC12, impacts its stability and interactions with other proteins, crucial for activating the NLRP3 inflammasome and triggering inflammation. However, the role of ZDHHC5 in NLRP3 palmitoylation remains uncertain due to conflicting findings. Palmitoylation at C88/91 is essential for STING activation and induction of type I interferons. It modulates the formation of multimeric complexes and downstream signaling pathways. GSDMD palmitoylation at C191 is necessary for pore formation and membrane translocation, while GSDME palmitoylation at C407/408 is associated with drug-induced pyroptosis. Moreover, palmitoylation of NOD1 and NOD2 influences their membrane recruitment and immune signaling pathways in response to bacterial peptidoglycans, acting as upstream regulators of pyroptosis. This review summarizes the important roles for palmitoylation in regulating the function of key pyroptosis-related proteins, shedding light on the intricate mechanisms governing immune responses and inflammation.
<P>PROBLEM TO BE SOLVED: To provide a method for identifying an agent inducing DOPAchrome tautomerase (TRP-2) expression, to provide a method for evaluating the cytoprotective activity of the agent, and to provide a method for using the agent inducing the expression.  <P>SOLUTION: There is provided the use of the agent inducing the DOPAchrome tautomerase expression as a protecting agent for hair follicle melanocytes in cosmetics. Furthermore, there are provided a specific cosmetic composition for fighting against canities comprising in a cosmetically acceptable medium at least one agent inducing the DOPAchrome tautomerase (TRP-2) expression, and uses thereof. In addition, there are provided a method for treating white hair, and a method for preserving natural pigmentation of gray or white hair by applying a cosmetic composition comprising at least one agent inducing the DOPAchrome tautomerase expression. Finally, there are provided the method for identifying the agent inducing the DOPAchrome tautomerase (TRP-2) expression, and the method for evaluating the cytoprotective activity of the agent.  <P>COPYRIGHT: (C)2011,JPO&INPIT
This is a multicenter (11 centers), prospective, randomized single blind study. This study has a 2-arm design assessing the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version to the bare metal Bx SONICTM stent. A total of 250 patients will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the eligibility criteria will be either randomized to the Sirolimus-eluting stent or the bare metal Bx SONIC stent. The investigator cannot be blind because the outer appearance of the system for the implant of the Sirolimus-eluting stent differs from that of the bare metal stent and will therefore immediately be recognized by the surgeon. However the patient will not know which stent will be implanted. Patients will be followed at 30 days, 9 and 12 months post-procedure, with all patients undergoing repeat angiography at 8 months. Additionally, medical costs associated with the index hospitalization and length of stay, and repeat hospitalizations and costs associated with other relevant medical resource use during the 1 year follow-up period will be collected and analyzed.
The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
Patients with hematologic malignancies or marrow aplasia are at increased risk of bleeding. While prophylactic platelet transfusions reduce the risk of bleeding compared with no prophylaxis, a significant risk of bleeding remains, with 43-54% of patients with a hematologic malignancy or marrow aplasia receiving chemotherapy, immunotherapy, or hematopoietic stem cell transplant (HSCT) experiencing WHO grade 2 or higher bleeding \[Stanworth et al. NEJM 2013; Gernsheimer et al, Blood 2020\]. Improved efficacy of therapeutic platelet transfusions would benefit this patient population. In vitro data suggests that cold-stored platelets have greater hemostatic responsiveness than those stored at room temperature.

This study will evaluate the feasibility of a randomized clinical trial comparing cold- and room temperature storage in patients admitted to hospital with a hematologic malignancy or marrow aplasia. Results will inform estimates of transfusion requirements and changes in bleeding severity for power calculations, inform management of a cold-stored platelet inventory, and will provide data on the use of cold-stored platelets in the Canadian health-care setting.
The present invention relates to a pharmaceutical composition for mitigating adverse effects induced by an anti-cancer drug and, more specifically, to a pharmaceutical composition for mitigating adverse effects induced by an anti-cancer drug comprising peptide of sequence No. 1 having an effect of mitigating adverse effects such as damage of marrow, nerve, kidney, etc. induced by an anti-cancer drug as an active ingredient. The peptide of sequence No. 1 can mitigate adverse effects induced by an anti-cancer drug and has relatively short amino acid sequence, thereby minimizing immunogenicity, toxicity adverse effects, etc., being mass-produced in an easy manner by being synthesized in an easy manner, and reducing costs. Accordingly, the peptide of sequence No. 1 can be used as an anti-cancer adjuvant.
Although all patients with cancer-associated thrombosis (CAT) have a high morbidity and mortality risk, certain groups of patients are particularly vulnerable. This may expose the patient to an increased risk of thrombotic recurrence or bleeding (or both), as the benefit-risk ratio of anticoagulant treatment may be modified. Treatment thus needs to be chosen with care. Such vulnerable groups include older patients, patients with renal impairment or thrombocytopenia, and underweight and obese patients. However, these patient groups are poorly represented in clinical trials, limiting the available data on which treatment decisions can be based. Meta-analysis of data from randomised clinical trials suggests that the relative treatment effect of direct oral factor Xa inhibitors (DXIs) and low molecular weight heparin (LMWH) with respect to major bleeding could be affected by advanced age. No evidence was obtained for a change in the relative risk-benefit profile of DXIs compared to LMWH in patients with renal impairment or of low body weight. The available, albeit limited, data do not support restricting the use of DXIs in patients with TAC on the basis of renal impairment or low body weight. In older patients, age is not itself a critical factor for choice of treatment, but frailty is such a factor. Patients over 70 years of age with CAT should undergo a systematic frailty evaluation before choosing treatment and modifiable bleeding risk factors should be addressed. In patients with renal impairment, creatine clearance should be assessed and monitored regularly thereafter. In patients with an eGFR less than 30mL/min/1.72m2, the anticoagulant treatment may need to be adapted. Similarly, platelet count should be assessed prior to treatment and monitored regularly. In patients with grade 3-4, thrombocytopenia (less than 50,000platelets/μL) treatment with a LMWH at a reduced dose should be considered. For patients with CAT and low body weight, standard anticoagulant treatment recommendations are appropriate, whereas in obese patients, apixaban may be preferred.